Detalhe da pesquisa
1.
Chromatin deregulation in disease.
Chromosoma
; 125(1): 75-93, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26188466
2.
Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer.
Proc Natl Acad Sci U S A
; 110(16): E1490-9, 2013 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-23576735
3.
The novel ß2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Haematologica
; 100(10): 1350-60, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26069288
4.
Cell-line-specific high background in the Proteasome-Glo assay of proteasome trypsin-like activity.
Anal Biochem
; 451: 1-3, 2014 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24486333
5.
Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites.
J Med Chem
; 56(3): 1262-75, 2013 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-23320547
6.
Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.
Chem Biol
; 18(5): 608-18, 2011 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-21609842